Katie Fanning, Mozart Therapeutics CEO
Mozart Therapeutics makes its official debut, jumping into the hot Treg R&D field with some big-name investors backing it
Treg cells have been getting more and more attention recently among autoimmune specialists. There’s been Jeff Bluestone’s Sonoma, the $157 million launch of GentiBio …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.